[Rheological properties of blood during pulsatile pharmacomechanical and continuous local thrombolysis].
BACKGROUND
The aim of the work was to find out whether the controlled administration of a thrombolytic directly into the arterial occlusion could prevent formation of the systemic lytic state, which may result in distant bleeding complications.


RESULTS
In patients subjected to pulsatile pharmacomechanical (94 patients) and local continual thrombolysis (74 patients) changes in blood and plasma viscosity, coagulation tests, fibrinogen levels and some other parameters were investigated.


CONCLUSIONS
Pulsatile pharmacomechanical thrombolysis, similarly to other forms of thrombolysis, is accompanied with systemic lytic state and the risk of unwanted resorption of the hemostatic thrombosis. Urokinase administration brings about regress of systemic changes, which is similar to the use of either tested thrombolytic administration. As treatment by the continual thrombolysis takes is approximately 40 times longer, the risk of systemic lytic state and bleeding complication growths.
Urbanová
R
R
II. interní klinika 3. LF UK a FN Královské Vinohrady, Praha. mbulv@lf1.cuni.cz
Bulvas
M
M
D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D001777:Blood Coagulation; D002406:Catheterization, Peripheral; D005260:Female; D018056:Hemorheology; D006801:Humans; D007511:Ischemia / Q000188:drug therapy; D007866:Leg / Q000098:blood supply; D008297:Male; D008875:Middle Aged; D010960:Plasminogen Activators / Q000008:administration & dosage*; D011673:Pulsatile Flow; D015912:Thrombolytic Therapy / Q000379:methods*; D013927:Thrombosis / Q000097:blood / Q000188:drug therapy; D014568:Urokinase-Type Plasminogen Activator / Q000008:administration & dosage*
D010960:Plasminogen Activators; D014568:Urokinase-Type Plasminogen Activator